News

Strongbridge Biopharma has begun dosing patients in another Phase 3 clinical trial of its Cushing’s syndrome therapy Recorlev (levoketoconazole). The company will enroll roughly 35 patients in the LOGICS (NCT03277690). Those participating in another Phase 3 trial, SONICS (NCT01838551), can enter the LOGICS study as well. LOGICS “marks an…

A very rare case of Cushing’s syndrome developing as a result of a large and also rare cancer of the nasal sinuses gives insights into how to screen and treat such an anomaly, of which fewer than 25 cases have been reported in literature. Paraneoplastic esthesioneuroblastoma (ENB), a very rare type…

Tumors located outside of the pituitary gland — most commonly small-cell lung cancer — can lead to ectopic Cushing’s syndrome, a new case report shows. The study with that finding, “Case-series of paraneoplastic Cushing syndrome in small-cell lung cancer,” was published in the journal Endocrinology, Diabetes…

Strongbridge Biopharma recently received a second patent from the U.S. Patent and Trademark Office covering the use of Recorlev (levoketoconazole) for the treatment of Cushing’s syndrome. The patent (No. 9,918,984) is titled “Methods and Compositions for Treating Diabetes, Metabolic Syndrome and Other Conditions” and will be active until Jan. 10,…

Repeat radiation therapy may be a reasonable third-line option for patients with persistent Cushing’s disease, after pituitary surgery and initial radiation therapy, a new study shows. Durable remission was seen in 50 percent of patients who received the treatment, according to the study. The research, titled, “Repeat…